Showing 5191-5200 of 5644 results for "".
- OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye Diseasehttps://modernod.com/news/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-in-a-mouse-model-of-dry-eye-disease/2476830/OKYO Pharma has announced potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of dry eye disease (DED) in mice. These preclinical efficacy data, identifying a lead drug candidate, will facilitate initiation of clinical
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/Staar Surgical announced that the FDA, in a letter dated August 23, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ Visian Implantable Collamer Lens for myopia, and EVO/EVO+ Visian Tor
- Topcon Launches the Maestro2 with Automated OCTAhttps://modernod.com/news/topcon-launches-the-maestro2-with-automated-octa/2476826/Topcon has announced the launch of the Maestro2 Automated OCT/Fundus Camera, now with OCTA. Building on the success of its predecessor, the 3D OCT-1 Maestro, the new Maestro2 adds even more clinical utility to its multimodality platform, according to a company news release. The Maestro2 is
- Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the US, the First and Only FDA-Approved Trifocal Lenshttps://modernod.com/news/alcon-introduces-acrysof-iq-panoptix-trifocal-iol-in-the-us-the-first-and-only-fda-approved-trifocal-lens/2476827/Alcon announced the FDA approval and the initial commercial launch of the AcrySof IQ PanOptix Trifocal IOL, the first and only trifocal lens approved in the United States. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate, and distance vision while reducing
- ProtoKinetix: Tests Show AAGP-Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestonehttps://modernod.com/news/protokinetix-tests-show-aagp-preserved-and-enabled-retinal-cells-to-mature-without-compromise-after-5-month-milestone/2476822/ProtoKinetix updated shareholders regarding ongoing third stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the company demonstrated the ability of AAGP to protect transplanted cells in a preclinical experimental model of retinal dege
- Quantel Medical Announces Acquisition of Optotek Medicalhttps://modernod.com/news/quantel-medical-announces-acquisition-of-optotek-medical/2476821/Quantel Medical announced that it is acquiring ophthalmic medical device maker Optotek Medical. This acquisition comes after a long collaboration between the two companies through the development and supply of devices
- High Levels of Exhaust Pollutants May Raise Risk for AMDhttps://modernod.com/news/high-levels-of-exhaust-pollutants-may-raise-risk-for-amd/2476819/Exposure to high levels of exhaust may raise the risk of age-related macular degeneration (AMD), a new study suggests, according to a Reuters report. In a study of nearly 40,000 people in Taiwan, researchers found that high levels o
- Trump Administration to Appeal Ruling Barring Proposed Drug Price Disclosure Policyhttps://modernod.com/news/trump-administration-to-appeal-ruling-barring-proposed-drug-price-disclosure-policy/2476816/The administration of US President Donald Trump plans to appeal a recent federal court decision striking down a Department of
- Nidek Launches the Mirante Scanning Laser Ophthalmoscopehttps://modernod.com/news/nidek-launches-the-mirante-scanning-laser-ophthalmoscope/2479546/Nidek has announced the launch of the Mirante Scanning Laser Ophthalmoscope. The Mirante is a multimodal fundus imaging platform that combines high definition SLO and OCT with ultra widefield imaging. The multimodal p
- Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Wet AMD and DMEhttps://modernod.com/news/aerie-pharmaceuticals-initiates-first-in-human-clinical-trial-of-ar-13503-sustained-release-intravitreal-implant-in-patients-with-wet-amd-and-dme/2476812/Aerie Pharmaceuticals announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release (SR) implant in patients with neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME). This multi-arm, 24-week study (AR-13503-CS20